Voltage-gated cation channel modulators for the treatment of stroke

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 579-592

  Gribkoff, Valentin K ^a   Winquist, Raymond J ^a  

^a Scion Pharmaceuticals Inc   (United States)

Author keywords

Acute focal stroke; Ischaemia; Maxi K channel; Neuroprotection; Voltage gated calcium channel; Voltage gated cation channel; Voltage gated sodium channel

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; ALTEPLASE; BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM ION; CROBENETINE; DIHYDROPYRIDINE DERIVATIVE; EXCITATORY AMINO ACID; FOSPHENYTOIN SODIUM; GABAPENTIN; ISRADIPINE; LAMOTRIGINE; LIDOCAINE; LUBELUZOLE; NICARDIPINE; NIMODIPINE; OMEGA CONOTOXIN MVIIA; PHENYLALKYLAMINE; PHENYTOIN; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM ION; RILUZOLE; SIPATRIGINE; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; TISSUE PLASMINOGEN ACTIVATOR; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM CONDUCTANCE; CALCIUM TRANSPORT; CELL DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE MODEL; DRUG EFFICACY; DRUG TARGETING; HUMAN; HYPERPOLARIZATION; MEMBRANE TRANSPORT; META ANALYSIS; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; POTASSIUM TRANSPORT; PREDICTION; PROBABILITY; RAT; REVIEW; SAMPLE SIZE; SEIZURE; SODIUM TRANSPORT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; CALCIUM CHANNELS; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEMS; HUMANS; NEUROPROTECTIVE AGENTS; POTASSIUM CHANNELS, VOLTAGE-GATED; SODIUM CHANNELS;

EID: 20344383229     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.579     Document Type: Review

References (173)

1. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 32:1598-1606.
2. FISHER M: Ongoing trials and future directions for acute ischemic stroke treatment. Adv. Neurol. (2003) 92:401-408.
3. LEES KR: Therapeutic interventions in acute stroke. Br. J. Clin. Pharmacol. (1992) 34:486-493.
4. ALBERTS MJ: tPA in acute ischemic stroke: United States experience and issues for the future. Neurology (1998) 51:S53-S55.
5. LAPCHAK PA: Development of thrombolytic therapy for stroke: a perspective. Expert. Opin. Investig. Drugs (2002) 11:1623-1632.
6. SACCO RL: Risk factors and outcomes for ischemic stroke. Neurology (1995) 45:S10-S14.
7. ARUNDIN E, MTYMIANSKI M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium (2003) 34:325-337.
8. DOBLE A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. (1999) 81:163-221.
9. SATTLER R, TYMANSKI M: Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol. Neurobiol. (2001) 24:107-129.
10. READ SJ, HIRANO T, DAVIS SM, DONNAN GA: Limiting neurological damage after stroke: a review of pharmacological treatment options. Drugs Aging (1999) 14:11-39.
11. SCHURR A: Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr. Drug Targets (2004) 5:603-618.
12. TATLISUMAK T, CARANO RA, TAKANO K et al.: Broad-spectrum cation channel inhibition by LOE 908 MS reduces infarct volume in vivo and postmortem in focal cerebral ischemia in the rat. Acta Neurochir. Suppl. (2000) 76:329-330.
13. CATTERALL WA, GOLDIN AL, WAXMAN SG: International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: sodium channels. Pharmacol. Rev. (2003) 55:575-578.
14. MARBAN E, YAMAGISHI T, TOMASELLI GF: Structure and function of voltage-gated sodium channels. J. Physiol. (1998) 508(Part 3):647-657.
15. CATTERALL WA, STRIESSNIG J, SNUTCH TP, PEREZ-REYES E: International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol. Rev. (2003) 55:579-581.
16. GUTMAN GA, CHANDY KG, ADELMAN JP et al.: International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol. Rev. (2003) 55:583-586.
17. GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI: Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist. (2001) 7:166-177.
18. CURRY SH: Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann. NY. Acad. Sci. (2003) 993:69-74.
19. FISHER M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc. Dis. (2004) 17(Suppl. 1):1-6.
20. WEINSTEIN PR, HONG S, SHARP FR: Molecular identification of the ischemic penumbra. Stroke (2004) 35:2666-2670.
21. CHOI DW: Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. (1985) 58:293-297.
22. CHOI DW, MAULUCCI-GEDDE M, KRIEGSTEIN AR: Glutamate neurotoxicity in cortical cell culture. J. Neurosci. (1987) 7:357-368.
23. COLLINS RC, DOBKIN BH, CHOI DW: Selective vulnerability of the brain: new insights into the pathophysiology of stroke. Ann. Intern. Med. (1989) 110:992-1000.
24. ZIVIN JA, GROTTA JC: Animal stroke models. They are relevant to human disease. Stroke (1990) 21:981-983.
25. ZIVIN JA, DEGIROLAMI U: Spinal cord infarction: a highly reproducible stroke model Stroke (1980) 11:200-202.
26. PULSINELLI WA, BRIERLEY JB, PLUM F: Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann. Neurol. (1982) 11:491-498.
27. SCHURR A, PAYNE RS, HEINE ME, RIGOR BM: Hypoxia, excitotoxicity, and neuroprotection in the hippocampal slice preparation. J. Neurosci. Methods (1995) 59:129-138.
28. GAGLIARDI RJ: Neuroprotection, excitotoxicity and NMDA antagonists. Arq. Neuropsiquiatr. (2000) 58:583-588.
29. ALBERDI E, SANCHEZ-GOMEZ MV, MARINO A, MATUTE C: Ca(2+) influx through AMPA or kainate receptors alone is sufficient to initiate excitotoxicity in cultured oligodendrocytes. Neurobiol Dis. (2002) 9:234-243.
30. GREENBERG DA: Calcium channels in neurological disease. Ann. Neurol. (1997) 42:275-282.
31. 2+-dependent proteases in ischemic neuronal death: a conserved 'calpain-cathepsin cascade' from nematodes to primates. Cell Calcium (2004) 36:285-293.
32. NEUMAR RW: Molecular mechanisms of ischemic neuronal injury. Ann. Emerg. Med. (2000) 36:483-506.
33. FISHER M, GINSBERG M: Current concepts of the ischemic penumbra: introduction Stroke (2004) 35:2657-2658.
34. KUMURA E, GRAF R, DOHMEN C, ROSNER G, HEISS WD: Breakdown of calcium homeostasis in relation to tissue depolarization: comparison between gray and white matter ischemia. J. Cereb. Blood Flow Metab. (1999) 19:788-793.
35. GRAF R, KATAOKA K, WAKAYAMA A et al.: Functional impairment due to white matter ischemia after middle cerebral artery occlusion in cats. Stroke (1990) 21:923-928.
36. ARIKKATH J, CAMPBELL KP: Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr. Opin. Neurobiol. (2003) 13:298-307.
37. BLACK JL III: The voltage-gated calcium channel gamma subunits: a review of the literature. J. Bioenerg. Biomembr. (2003) 35:649-660.
38. WHEELER DB, RANDALL A, SATHER WA, TSIEN RW: Neuronal calcium channels encoded by the α1A subunit and their contribution to excitatory synaptic transmission in the CNS. Prog. Brain Res. (1995) 105:65-78.
39. SNUTCH TP, SUTTON KG, ZAMPONI GW: Voltage-dependent calcium channels-beyond dihydropyridine antagonists. Curr. Opin. Pharmacol. (2001) 1:11-16.
40. ALLEN NJ, KARADOTTIR R, ATTWELL D: A preferential role for glycolysis in preventing the anoxic depolarization of rat hippocampal area CA1 pyramidal cells. J. Neurosci. (2005) 25:848-859.
41. PEREZ-REYES E: Three for T: molecular analysis of the low voltage-activated calcium channel family. Cell Mol. Life Sci. (1999) 56:660-669.
42. 2+ channels. J. Biol. Chem. (2000) 275:39786-39792.
43. ZEILHOFER HU, BLANK NM, NEUHUBER WL, SWANDULLA D: Calcium-dependent inactivation of neuronal calcium channel currents is independent of calcineurin. Neuroscience (2000) 95:235-241.
44. TRIGGLE DJ: Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev. Technol. (2003) 1:719-733.
45. YUEN P, SCHELKUN RM, SZOKE B,TARCZY-HORNOCH K: Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg. Med. Chem. Lett. (1998) 8:2415-2418.
46. TEODORI E, BALDI E, DEI S et al.: Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain. J. Med. Chem. (2004) 47:6070-6081.
47. HU LY, RYDER TR, RAFFERTY MF et al.: Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties. J. Med. Chem. (1999) 42:4239-4249.
48. HU LY, RYDER TR, RAFFERTY MF et al.: Neuronal N-type calcium channel blockers: a series of 4-piperidinylaniline analogs with analgesic activity. Drug Des. Discov. (2000) 17:85-93.
49. VALENTINO K, NEWCOMB R, GADBOIS T et al.: A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA (1993) 90:7894-7897.
50. MILJANICH GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. (2004) 11:3029-3040.
51. CATTERALL WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. (1999) 79:441-456.
52. LAI J, PORRECA F, HUNTER JC, GOLD MS: Voltage-gated sodium channels and hyperalgesia. Ann. Rev. Pharmacol. Toxicol. (2004) 44:371-397.
53. TAYLOR CP, NARASIMHAN LS: Sodium channels and therapy of central nervous system diseases. Adv. Pharmacol. (1997) 39:47-98.
54. WAXMAN SG, CUMMINS TR, DIB-HAJJ S, FJELL J, BLACK JA: Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve (1999) 22:1177-1187.
55. 2+ channels controlling presynaptic release of glutamate. Ann. NY. Acad. Sci. (1995) 765:210-229.
56. RAGSDALE D, SAVOLI M: Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Brain Res. Rev. (1998) 26:16-28.
57. COSFORD ND, MEINKE PT, STAUDERMAN KA, HESS SD: Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy. Curr. Drug Targets CNS Neurol. Disord. (2002) 1:81-104.
58. KACZOROWSKI GJ, GARCIA ML: Pharmacology of voltage-gated and calcium-activated potassium channels. Curr. Opin. Chem. Biol. (1999) 3:448-458.
59. WEI L, YU SP, GOTTRON F et al.: Potassium channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and in vivo. Stroke (2003) 34:1281-1286.
60. GRIBKOFF VK, STARRETT JE Jr., DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471-477.
61. CHENEY JA, WEISSER JD, BAREYRE FM et al.: The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J. Cereb. Blood Flow Metab. (2001) 21:396-403.
62. HEWAWASAM P, DING M, CHEN N et al.: Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection. Bioorg. Med. Chem. Lett. (2003) 13:1695-1698.
63. GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI: Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist. (2001) 7:166-177.
64. GRIBKOFF VK: The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin. Ther. Targets (2003) 7:737-748.
65. SMALL DL, MONETTE R, BUCHAN AM, MORLEY P: Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation. Brain Res. (1997) 753:209-218.
66. KRIEGLSTEIN J, LIPPERT K, POCH G: Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology (1996) 35:1737-1742.
67. KITTAKA M, GIANNOTTA SL, ZELMAN V et al.: Attenuation of brain injury and reduction of neuron-specific enolase by nicardipine in systemic circulation following focal ischemia and reperfusion in a rat model. J. Neurosurg. (1997) 87:731-737.
68. HORN J, DE HAAN RJ, VERMEULEN M, LUITEN PG, LIMBURG M: Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke (2001) 32:2433-2438.
69. LAZAREWICZ JW, PLUTA R, PUKA M,SALINSKA E: Diverse mechanisms of neuronal protection by nimodipine in experimental rabbit brain ischemia. Stroke (1990) 21:IV108-IV110.
70. 2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration (1995) 4:307-314.
71. TALLY PW, SUNDT TM Jr, ANDERSON RE: Improvement of cortical perfusion, intracellular pH, and electrocorticography by nimodipine during transient focal cerebral ischemia. Neurosurgery (1989) 24:80-87.
72. ZAPATER, P, MORENO J, HORGA JF: Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res. (1997) 772:57-62.
73. OHTA S, SMITH ML, SIESJO BK: The effect of a dihydropyridine calcium antagonist (isradipine) on selective neuronal necrosis. J. Neurol. Sci. (1991) 103:109-115.
74. CAMPBELL CA, MacKAY KB, PATEL S et al.: Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp. Neurol. (1997) 148:45-50.
75. CHANDRA S, WHITE RF, EVERDING D et al.: Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia. Pharmacology (1999) 58:292-299.
76. BAILEY SJ, WOOD NI, SAMSON NA et al.: Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. Stroke (1995) 26:2177-2183.
77. BURNS LH, JIN Z, BOWERSOX SS: The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. J. Vasc. Surg. (1999) 30:334-343.
78. PEREZ-PINZON MA, YENARI MA, SUN GH, KUNIS DM, STEINBERG GK: SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci. (1997) 153:25-31.
79. YENARI MA, PALMER JT, SUN GH et al.: Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res. (1996) 739:36-45.
80. MARAIS E, KLUGBAUER N, HOFMANN F: Calcium channel α(2)δ subunits-structure and gabapentin binding. Mol. Pharmacol. (2001) 59:1243-1248.
81. STAHL SM: Mechanism of action of α2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry (2004) 65:1033-1034.
82. 2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropharmacology (2002) 42:353-366.
83. LAGREZE WA, MULLER-VELTEN R, FEUERSTEIN TJ: The neuroprotective properties of gabapentin-lactam. Graefes Arch. Clin. Exp. Ophthalmol. (2001) 239:845-849.
84. WILLIAMS AJ, TORTELLA FC, LU XM, MORETON JE, HARTINGS JA: Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. J. Pharmacol. Exp. Ther. (2004) 311:220-227.
85. AZCONA A, LATASTE X: Isradipine in patients with acute ischaemic cerebral infarction. An overview of the ASCLEPIOS Programme. Drugs (1990) 40(Suppl. 2):52-57.
86. UEMATSU D, GREENBERG JH, HICKEY WF, REIVICH M: Nimodipine attenuates both increase in cytosolic free calcium and histologic damage following focal cerebral ischemia and reperfusion in cats. Stroke (1989) 20:1531-1537.
87. HORN J, DE HAAN RJ, VERMEULEN M, LIMBURG M: Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke (2001) 32:461-465.
88. LEGAULT C, FURBERG CD, WAGENKNECHT LE et al.: Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke (1996) 27:593-598.
89. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group. Lancet (1990) 336:1205-1209.
90. AHMED N, NASMAN P, WAHLGREN NG: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke (2000) 31:1250-1255.
91. FOGELHOLM R, ERILA T, PALOMAKI H, MURROS K, KASTE M: Effect of nimodipine on final infarct volume after acute ischemic stroke. Cerebrovasc. Dis. (2000) 10:189-193.
92. HEISS WD, HOLTHOFF V, PAWLIK G, NEVELING M: Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J. Cereb. Blood Flow Metab (1990) 10:127-132.
93. HULSER PJ, KORNHUBER AW, KORNHUBER HH: Treatment of acute stroke with calcium antagonists. Eur. Neurol. (1990) 30(Suppl. 2):35-38.
94. INFELD B, DAVIS SM, DONNAN GA et al.: Nimodipine and perfusion changes after stroke. Stroke (1999) 30:1417-1423.
95. KASTE M, FOGELHOLM R, ERILA T et al.: A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke (1994) 25:1348-1353.
96. PACI A, OTTAVIANO P, TRENTA A et al.: Nimodipine in acute ischemic stroke: a double-blind controlled study. Acta Neurol. Scand. (1989) 80:282-286.
97. NAG D, GARG RK, VARMA M: A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke. Indian J. Physiol Pharmacol. (1998) 42:555-558.
98. Neuroprotection as initial therapy in acute stroke. Third report of an Ad Hoc Consensus Group meeting. The European Ad Hoc Consensus Group. Cerebrovasc. Dis. (1998) 8:59-72.
99. ROMERO M, SANCHEZ I, PUJOL MD: New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr. Med. Chem. Cardiovasc. Hematol. Agents (2003) 1:113-141.
100. MENZLER S, BIKKER JA, SUMAN-CHAUHAN N, HORWELL DC: Design and biological evaluation of non-peptide analogues of ω-conotoxin MVIIA. Bioorg. Med. Chem. Lett. (2000) 10:345-347.
101. SEKO T, KATO M, KOHNO H et al.: Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. Bioorg. Med. Chem. Lett. (2001) 11:2067-2070.
102. SONG Y, BOWERSOX SS, CONNOR DT et al.: (S)-4-Methyl-2-(methylamino) pentanoic acid [4, 4-bis(4-fluorophenyl) butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of pain. J. Med. Chem. (2000) 43:3474-3477.
103. BARONE FC, LYSKO PG, PRICE WJ et al.: SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke (1995) 26:1683-1689.
104. CAMPBELL CA, BARONE FC, BENHAM CD et al.: Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke. Eur. J. Pharmacol. (2000) 401:419-428.
105. KASHIWAGI F, KATAYAMA Y, IGARASHI H et al.: Effect of a new calcium antagonist (SM-6586) on experimental cerebral ischemia. Acta Neurochir. Suppl. (Wien.) (1994) 60:289-292.
106. XIE Y, DENGLER K, ZACHARIAS E, WILFFERT B, TEGTMEIER F: Effects of the sodium channel blocker tetrodotoxin (TTX) on cellular ion homeostasis in rat brain subjected to complete ischemia. Brain Res. (1994) 652:216-224.
107. FARBER NB, JIANG XP, HEINKEL C, NEMMERS B: Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry (2002) 7:726-733.
108. ASHTON D, WILLEMS R, WYNANTS J et al.: Altered Na(+)-channel function as an in vitro model of the ischemic penumbra: action of lubeluzole and other neuroprotective drugs Brain Res. (1997) 745:210-221.
109. CALABRESI P, PICCONI B, SAULLE E et al: Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke (2000) 31:766-772.
110. + channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur. J. Pharmacol (1997) 332:121-131.
111. SHUAIB A, MAHMOOD RH, WISHART T et al.: Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res. (1995) 702:199-206.
112. MELDRUM BS: Lamotrigine-a novel approach. Seizure. (1994) 3(Suppl. A):41-45.
113. SCHWARTZ G, FEHLINGS MG: Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J. Neurosurg. Spine (2001) 94:245-256.
114. STOVER JF, BEYER TF, UNTERBERG AW. Riluzole reduces brain swelling and contusion volume in rats following controlled cortical impact injury. J. Neurotrauma (2000) 17:1171-1178.
115. LEI B, POPP S, CAPUANO-WATERS C, COTTRELL JE, KASS IS: Lidocaine attenuates apoptosis in the ischemic penumbra and reduces infarct size after transient focal cerebral ischemia in rats. Neuroscience (2004) 125:691-701.
116. ROGAWSKI MA, LOSCHER W: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. (2004) 10:685-692.
117. WAXMAN SG, CUMMINS TR, DIB-HAJJ SD, BLACK JA. Voltage-gated sodium channels and the molecular pathogenesis of pain: a review. J. Rehab. Res. Dev. (2000) 37:517-528.
118. DEVULDER J, CROMBEZ E, MORTIER E: Central pain: an overview. Acta Neurol. Belg. (2002) 102:97-103.
119. ANGER T, MADGE DJ, MULLA M, RIDDALL D: Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J. Med. Chem. (2001) 44:115-137.
120. CALLAWAY JK, CASTILLO-MELENDEZ M, GIARDINA SF et al.: Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence. Neuropharmacology (2004) 47:146-155.
121. CALLAWAY JK: Investigation of AM-36: a novel neuroprotective agent. Clin. Exp. Pharmacol. Physiol (2001) 28:913-918.
122. DAVE JR, LIN Y, VED HS et al.: RS-100642-198, a novel sodium channel blocker, provides differential neuroprotection against hypoxia/hypoglycemia, veratridine or glutamate-mediated neurotoxicity in primary cultures of rat cerebellar neurons. Neurotox. Res. (2001) 3:381-395.
123. 2+ channel blocker in a rodent model of transient focal ischaemia. Neurotox. Res. (2002) 4:655-661.
124. CARTER AJ, GRAUERT M, PSCHORN U et al.: Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. Proc. Natl. Acad. Sci. USA (2000) 97:4944-4949.
125. CALABRESI P, STEFANI A, MARFIA GA et al.: Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. Exp. Neurol. (2000) 162:171-179.
126. DIENER HC, CORTENS M, FORD G et al.: Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke (2000) 31:2543-2551.
127. GANDOLFO C, SANDERCOCK P, CONTI,M: Lubeluzole for acute ischaemic stroke. Cochrane. Database. Syst. Rev. (2002):CD001924.
128. GROTTA J: Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole Cerebrovasc. Dis. (2001) 12:258-263.
129. MUIR KW, HOLZAPFEL L, LEES KR: Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc. Dis. (2000) 10:431-436.
130. MEYTHALER J: BIII-890-CL. Boehringer Ingelheim. Curr. Opin. Investig. Drugs (2002) 3:1733-1735.
131. + channel openers on β-amyloid induced cerebrovascular endothelial dysfunction. Neurol. Res. (1999) 21:345-351.
132. WEI L, YU SP, GOTTRON F et al.: Potassium channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and in vivo. Stroke (2003) 34:1281-1286.
133. + channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release. J. Neurosci. (2001) 21:9585-9597.
134. DWORETZKY SI, BOISSARD CG, LUM-RAGAN JT et al.: Phenotypic alteration of a human BK (hSlo) channel by hSlobeta subunit coexpression: changes in blocker sensitivity, activation/relaxation and inactivation kinetics, and protein kinase A modulation. J. Neurosci. (1996) 16:4543-4550.
135. BRENNER R, JEGLA TJ, WICKENDEN A, LIU Y, ALDRICH RW: Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J. Biol. Chem. (2000) 275:6453-6461.
136. CHANG CP, DWORETZKY SI, WANG J, GOLDSTEIN ME: Differential expression of the alpha and beta subunits of the large-conductance calcium-activated potassium channel: implication for channel diversity Brain Res. Mol. Brain Res. (1997) 45:33-40.
137. BEHRENS R, NOLTING A, REIMANN F et al.: hKCNMB3 and hKCNMB4, cloning and characterization of two members of the large-conductance calcium-activated potassium channel beta subunit family FEBS Lett. (2000) 474:99-106.
138. HA TS, HEO MS, PARK CS: Functional effects of auxiliary beta4-subunit on rat large-conductance Ca(2+)-activated K(+) channel. Biophys. J. (2004) 86:2871-2882.
139. FURY M, MARX SO, MARKS AR: Molecular BKology: the study of splicing and dicing. Sci. STKE (2002) 2002:E12.
140. TIAN L, DUNCAN RR, HAMMOND MS et al.: Alternative splicing switches potassium channel sensitivity to protein phosphorylation. J. Biol. Chem. (2001) 276:7717-7720.
141. CIBULSKY SM, FEI H, LEVITAN IB: Syntaxin-1A binds to and modulates the Slo calcium-activated potassium channel via an interaction that excludes syntaxin binding to calcium channels. J. Neurophysiol. (2004).
142. JIN P, WEIGER TM, WU Y, LEVITAN IB: Phosphorylation-dependent functional coupling of hSlo calcium-dependent potassium channel and its hβ4 subunit. J. Biol. Chem. (2002) 277:10014-10020.
143. ALIOUA A, TANAKA Y, WALLNER M et al.: The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J. Biol. Chem. (1998) 273:32950-32956.
144. KEMP PJ, PEERS C, LEWIS A: Oxygen sensing by human recombinant large conductance, calcium-activated potassium channels. Regulation by acute hypoxia. Adv. Exp. Med. Biol. (2003) 536:209-215.
145. RIESCO-FAGUNDO AM, PEREZ-GARCIA MT, GONZALEZ C, LOPEZ-LOPEZ JR: O(2) modulates large-conductance Ca(2+)-dependent K(+) channels of rat chemoreceptor cells by a membrane-restricted and CO-sensitive mechanism. Circ. Res. (2001) 89:430-436.
146. LIU H, MOCZYDLOWSKI E, HADDAD GG: O(2) deprivation inhibits Ca(2+)-activated K(+) channels via cytosolic factors in mice neocortical neurons. J. Clin. Invest (1999) 104:577-588.
147. JIANG C, HADDAD GG: Oxygen deprivation inhibits a K+ channel independently of cytosolic factors in rat central neurons. J. Physiol. (1994) 481 (Part 1): 15-26.
148. HARTNESS ME, BRAZIER SP, PEERS C et al.: Post-transcriptional control of human maxiK potassium channel activity and acute oxygen sensitivity by chronic hypoxia. J. Biol. Chem. (2003) 278:51422-51432.
149. WILLIAMS SE, WOOTTON P, MASON HS et al.: Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. Science (2004) 306:2093-2097.
150. 2+-activated K channel of the BK-type in the inner mitochondrial membrane of a human glioma cell line. Biochem. Biophys. Res. Commun. (1999) 257:549-554.
151. RUNDEN-PRAN E, HAUG FM, STORM JF, OTTERSEN OP: BK channel activity determines the extent of cell degeneration after oxygen and glucose deprivation: a study in organotypical hippocampal slice cultures. Neuroscience (2002) 112:277-288.
152. McKAY MC, DWORETZKY SI, MEANWELL NA et al.: Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. J. Neurophysiol. (1994) 71:1873-1882.
153. + channels in cerebellar granule cells. Neuroreport (1994) 5:1001-1004.
154. HEWAWASAM P, ERWAY M, THALODY G et al.: The synthesis and structure-activity relationships of 1,3-diaryl 1,2,4-(4H)-triazol-5-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel opener targeted for urge urinary incontinence. Bioorg. Med. Chem. Lett. (2002) 12:1117-1120.
155. HEWAWASAM P, ERWAY M, MOON SL et al.: Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties. J. Med. Chem. (2002) 45:1487-1499.
156. HEWAWASAM P, FAN W, KNIPE J et al.: The synthesis and structure-activity relationships of 4-aryl-3-aminoquinolin-2-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel openers targeted for post-stroke neuroprotection. Bioorg. Med. Chem. Lett. (2002) 12:1779-1783.
157. HEWAWASAM P, GRIBKOFF VK, PENDRI Y et al.: The synthesis and characterization of BMS-204352 (MaxiPost) and related 3-fluorooxindoles as openers of maxi-K potassium channels. Bioorg. Med. Chem. Lett. (2002) 12:1023-1026.
158. SIVARAO DV, NEWBERRY K, LANGDON SW et al.: Effect of BMS-223131 a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress aggravated colonic motility and visceral nociception. J. Pharmacol. Exp. Ther. (2005)
159. ROMINE JL, MARTIN SW, GRIBKOFF VK et al.: 4,5-diphenyltriazol-3-ones: openers of large-conductance Ca(2+)-activated potassium (maxi-K) channels. J. Med. Chem. (2002) 45:2942-2952.
160. GRIBKOFF VK, LUM-RAGAN JT, BOISSARD CG et al.: Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol. Pharmacol. (1996) 50:206-217.
161. GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI: The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv. Pharmacol. (1997) 37:319-348.
162. 2+-dependent large-conductance potassium channels: symmetrical pharmacophore and electrophysiological evaluation of bisphenols. Bioorg. Med. Chem. Lett. (2003) 13:1437-1439.
163. GIANGIACOMO KM, KAMASSAH A, HARRIS G, McMANUS OB: Mechanism of maxi-K channel activation by dehydrosoyasaponin-I. J. Gen. Physiol (1998) 112:485-501.
164. 2+. Neuropharmacology (1996) 35:903-914.
165. + channels by novel benzimidazolone. Eur. J. Pharmacol. (1994) 251:53-59.
166. SCHRODER RL, STROBAEK D, OLESEN SP, CHRISTOPHERSEN P: Voltage-independent KCNQ4 currents induced by (±)BMS-204352. Pflugers Arch. (2003) 446:607-616.
167. JENSEN BS: BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev. (2002) 8:353-360.
168. Recommendations for standards regarding preclinical neuroprotective and restorative drug development Stroke (1999) 30:2752-2758.
169. FISHER M: Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke (2003) 34:1539-1546.
170. DAVIS M, MENDELOW AD, PERRY RH, CHAMBERS IR, JAMES OF: The effect of age on cerebral oedema, cerebral infarction and neuroprotective potential in experimental occlusive stroke. Acta Neurochir. Suppl. (Wien.) (1994) 60:282-284.
171. DAVIS M, PERRY RH, MENDELOW AD: The effect of non-competitive N-methyl-D-aspartate receptor antagonism on cerebral oedema and cerebral infarct size in the aging ischaemic brain. Acta Neurochir. Suppl. (1997) 70:30-33.
172. SATO K, HAYASHI T, SASAKI C et al.: Temporal and spatial differences of PSA-NCAM expression between young-adult and aged rats in normal and ischemic brains. Brain Res. (2001) 922:135-139.
173. LINDNER MD, GRIBKOFF VK, DONLAN NA, JONES TA: Long-lasting functional disabilities in middle-aged rats with small cerebral infarcts. J. Neurosci. (2003) 23:10913-10922.